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Abstract: 
Acute gastroenteritis is very much common among diseases which causes mortality among under-developed countries. 
Seventy percent of the acute gastroenteritis episodes is because of viruses. An effective approach to treat the onset of 
acute gastroenteritis is oral rehydration therapy. It is also suggested and recommended as well as first-line 
management therapy. However, ORS is a simple solution which is underused. Underuse of oral rehydration therapy 
is explained through an onset of vomiting. Antiemetics are not suggested in regular routine for the treatment of acute 
gastroenteritis but they are still prescribed. Ondansetron is much-explored antiemetics which enhances the role of 
oral rehydration therapy compliance and it also reduces hospitalization. Recent studies produced few pieces of 
evidence; on the basis of these evidence the recommendation of antiemetics have largely shifted as per the new 
guidelines. 
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INTRODUCTION: 
Gastroenteritis refers to an inflammation of 
gastrointestinal tract mucous membranes and it has the 
features of vomiting and diarrhoea commonly reported 
in children [1]. Globally, every year about 3 – 5 billion 
children get affected by Gastroenteritis with 12% of 
mortality rate [2]. Health system suffers from the onset 
of Gastroenteritis. Acute gastroenteritis causes 
increased hospitalization and visits to healthcare 
professionals. Hospitalization is higher among under-
developed countries. Every year nine out of one 
thousand are hospitalized in the USA every year with 
an average age of under five years [4]. However, 
hospitalization in China is more than any other country 
as 26 out of 1000 are hospitalized every year [5]. 
Better state of children is due to better dietary habits 
of the children in developed countries. Hospitalization 
decision does not simply rely on the clinical setting but 
it is also affected through social factors. Most 
important etiological factors relate to viruses which 
cause 70% of acute gastroenteritis episodes [6]. 
Etiological agents have identified more than twenty 
viruses [7]. About 30% – 70% hospitalization is 
because of rotavirus all over the world; whereas, 4% – 
24% due to acute gastroenteritis [8]. Rotavirus is a 
prototypical virus as it commonly causes 
gastroenteritis among children ultimately requiring 
intravenous fluid. Physician visits and hospitalization 
is mostly associated with rotavirus [9]. Gastroenteritis 
leads to an increased economic burden on the 
healthcare system of any country. An author reported 
disease severity among children having fever and 
vomiting (63%), vomiting and diarrhoea (21%), fever 
and diarrhoea (7%), fever and vomiting (4%), fever 
(3%) and vomiting (2%) [10]. Vomiting is among the 
most common features of acute gastroenteritis which 
requires intravenous therapy [11]. 
 
Comparison of oral rehydration and intravenous 
therapy:  
Almost every paediatrics association recommends the 
use of oral rehydration therapy as the first choice of 
treatment to manage acute gastroenteritis except 
severely affected cases of dehydration [12]. Various 
randomized trials also explain the effectiveness of oral 
rehydration therapy for mild to moderate dehydrated 
cases. No clinical difference was reported in these 
trials in the use of both strategies. Less hospitalization 
was reported among those who were treated with oral 
hydration therapy than intravenous therapy. Moreover, 
intravenous therapy also accompanies phlebitis risk 
which is not linked with oral rehydration. ORS is an 
achievement of 20th-century medical advances which 
is unanimously supported by various paediatrics 
associations. While judging the effectiveness of both 
therapies the top priority of acute gastroenteritis 
treatment goes to oral rehydration therapy. Cost and 
safety are also hot issues as oral rehydration therapy 
are successful in the community management of 
children. Oral rehydration therapy saves money and 
reduces hospital stay. 
 
Why oral rehydration therapy is underused?  
Such reasons are not fully known as there are variables 
involved factors such as a physician, patients, 
environment and parental concerns. In most of the 
cases, physicians were not fully aware of the AAP 
guidelines of treating moderate and mild dehydration. 
Intravenous therapy is likely chosen when the OPD is 
crowded and waiting time is more than expected, 
parental concerns about actual dehydration level and 
severity level of the dehydration. In the case of 
diarrhoea, 8% of physicians opt for the intravenous 
therapy. Patients no taking water is another reason for 
98% of intravenous therapy along with an onset of 
vomiting. 
 
The pathophysiology of vomiting and antiemetic 
medications mechanism:  
Vomiting can be correlated with retching and nausea 
[13]. It is a state in which stomach contents expel 
through the mouth in a violent and unpleasant way. 
The vomiting centre located at lateral reticular medulla 
oblongata integrates and controls vomiting. It is close 
to other centres which regulate vasomotor, respiration 
and other autonomic functions which can also be 
helpful in the act of vomiting. Emetic stimuli may 
directly be received from vomiting centre or it may 
arrive from chemoreceptor trigger zone. The 
chemoreceptor trigger zone is exposed to bloodstream 
and cerebrospinal fluid. Psychological stress like fear 
can act on the limbic system and cerebral cortex 
through vomiting centre can induce vomiting. The 
vestibular system stimulates vomiting as a result of 
motion sickness, its impulses come from inner ear 
labyrinth to vomiting centre. However, vomiting 
mechanism of gastroenteritis is still unknown. A 
strong relation is also made with the peripheral stimuli 
that arise from the gastrointestinal tract primarily via 
serotonin stimulation or vagus nerve (5-
hydroxytryptamine 3 (5HT3) receptors) located in the 
gut [14]. The objective of antiemetic therapy is to 
depress the vomiting centre, chemoreceptor centre, 
inhibition of chemoreceptor zone pulses receiving at 
vomiting centre and inhibition of peripheral receptors 
pulses to the vomiting centre. All areas involved in the 
pathogenesis of vomiting are full of dopaminergic, 
serotoninergic, muscarinic and histaminic receptors 
[15]. 
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ANTIEMETIC MEDICATIONS (SEROTONIN 
5HT3 RECEPTOR ANTAGONISTS) 
Ondansetron:  
Ondansetron is a derivative of carbazole and best-
known serotonin (5HT3) receptor antagonists which 
are available as a medication since 1991. It blocks the 
receptors at sympathetic nerves and vagus with the 
help of chemoreceptor trigger zones. Ondansetron 
possesses no antidopaminergic features and effective 
against migraine induced vomiting, acetaminophen 
poisoning and procedural sedation. It produces 
positive outcomes to control vomiting in 
gastroenteritis. Various authors have also reviewed it 
for emesis cessation, hospital admission, intravenous 
rehydration fluid, medications adverse effects and care 
resumption. Ondansetron profile for safety is fine in 
the management of gastroenteritis with a repeated side 
effect of diarrhoea [16]. Bryson reported similar 
adverse events of ondansetron as of placebo. There 
were no signs of sedation or extrapyramidal reactions. 
Few trials also report headache, constipation and 
fatigue as common adverse effects. The tolerability of 
Ondansetron is very good and carried low potential. 
Gastrointestinal tract completely absorbs it and it is 
also metabolized as well. It recommended dose varies 
according to the weight of the children which varies 
from 0.1 to 0.15 mg to 4 mg maximum. A single dose 
is sufficient for the management of gastrointestinal 
vomiting. 
 
Other antiemetic medications:  
Other antiemetic medications include dimenhydrinate, 
Promethazine, Metoclopramide, Droperidol, 
Domperidone, Domperidone, Prochlorperazine, 
Trimethobenzamide and Dexamethasone.  
 
Table: Detailed analysis of various drugs 
 
Drug No. of RCT(s) Route/dose Consideration 
Ondansetron 7 
PO: 2 mg for Bw 8–15 kg  
Minimal adverse effects, with good 
evidence for reduced admission and 
intravenous therapy 
4 mg for Bw 15–30 kg 8 mg for 
Bw .30 kg iv: 0.1–0.15 mg/kg 
Bw 
Dimenhydrinate 1 PO/PR/iM/iv: 1.25 mg/kg Bw Sedative effect 
Promethazine 1 PO/PR/iM/iv: 0.25-1 mg/kg Bw FDA black box warning 
Metoclopramide 2 PO/iM/iv: 0.1 mg/kg Bw 
High frequency of extra-pyramidal 
reaction 
Droperidol 0 iM/iv: 0.05–0.06 mg/kg Bw FDA black box warning 
Domperidone 2 
PO: 0.3–0.6 mg/kg Bw  
No iv as increase cardiac arrhythmias PR: ,2 yr: 10 mg, 2–6yr:  
30 mg, .6 yr: 60 mg 
Prochlorperazine 0 
PO: 0.1–0.2 mg/kg Bw PR: 0.1–
0.2 mg/kg Bw iM: 0.15 mg/kg 
Bw 
Not recommended if ,2y/iv dosing not 
recommended in pediatric patients 
Trimethobenzamide 2 
PO: 4–5 mg/kg Bw  PR form was removed from the 
manufacture/iM/iv routes not 
recommended in pediatric patients PR: 4–5 mg/kg Bw 
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Few are discussed in detail below: 
 
Dimenhydrinate:  
Dimenhydrinate blocks H-I receptors, muscarinic-
cholinergic receptors in vomiting centre and 
vestibular. It can be used conveniently via rectal, oral, 
intravenous or intramuscular routes with a 
recommended dose of 1.25 to 50 mg [17]. It also treats 
postoperative nausea, vomiting, radiation sickness, 
motion sickness and labyrinthine function disorder. It 
is more expensive than ondansetron. The major 
concern of dimenhydrinate is its sedative effect which 
can risk the oral rehydration fluids intake which can 
even enhance the dehydration level. 
 
Promethazine:  
Promethazine has activities like anti-dopaminergic 
and anticholinergic and it is derived from 
phenothiazines. It is used for the management of 
motion sickness, vomiting and postoperative nausea. 
It can be used conveniently via rectal, oral, 
intravenous or intramuscular routes with a 
recommended dose of 0.25 to 25 mg. It is absorbed 
easily and also among less expensive medications. It 
poses serious adverse outcomes such as oversedation, 
respiratory depression, hallucinations, agitation, 
dystonic reactions and seizures [18]. It is suggested not 
to prescribe to those children already taking other 
drugs having respiratory depressant effects as these 
effects may further aggravate. 
 
Metoclopramide:  
Metoclopramide is a derivative of chlorinated 
procainamide that acts as a D-2 receptor antagonist. It 
also possesses peripheral and central actions which 
increase vomiting and nausea by lowering impulses to 
gastric sphincter tone, chemoreceptor trigger zone, 
increases gastric emptying, stimulates gastric motility 
and small transit time of intestine. It also prevents 
chemotherapy-induced vomiting, vomiting, 
postoperative nausea and pregnancy-related vomiting 
and nausea [19]. Its severe effects include seizures, 
methemoglobinemia, neuroleptic malignant 
syndrome, gynecomastia and hemoglobinemia. 
 
Droperidol: Droperidol is applied for the 
maintenance of tranquilization or sedation to reduce 
vomiting and nausea and anti-anxiety activity. 
Droperidol is a potent D-2 receptor antagonist with the 
weaker activity of antihistamine and anticholinergic. It 
acts in the peripheral and central way. Studies prove it 
as a postoperative antiemetic agent. The anti-nausea 
effect is good with reduced antiemetic effect with a 
recommended dose of 0.05 mg – 0.06 mg which can 
be managed intravenously and intramuscularly. 
Droperidol is not suggested for children under two 
years of age due to efficacy and safety. 
 
Domperidone:  
Domperidone is known as D-2 receptor antagonist 
which can accelerate emptying time of gastric and also 
acts on chemoreceptor trigger zone. It also treats 
postoperative vomiting and nausea. Presently, it is 
available suppository and oral administration due to 
cardiac arrhythmias caused by higher dose through 
intravenous route. Its suggested dose starts from a 
minimum of 0.3 mg – 0.6 mg and up to a maximum of 
25 mg. Its adverse effects include cardiac arrest and 
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ventricular arrhythmias. Its penetration into the 
nervous system is poor so it does not cause any 
significant adverse effect.  
 
SHIFTING PHARMACOEPIDEMIOLOGY OF 
ANTIEMETIC MEDICATIONS: 
Pfeil investigated the antiemetic medications pattern 
among children (0 – 9) years of age who were 
diagnosed with gastroenteritis infection back in 2005 
[20]. The author investigated distribution and 
percentage of acute gastroenteritis among patients 
selected from different regions. Every patient was 
prescribed with dopaminergic or antihistamines 
receptor antagonists. Most of the German patients 
were prescribed with dimenhydrinate. Various 
backgrounds prescribed different drugs such as 
promethazine, dopamine receptor antagonist and 
ondansetron. Different countries showed the 
contrasting prescription pattern for different drugs. 
Moreover, ondansetron’s therapeutic efficacy is 
relatively current. Physicians are starting the 
prescription of ondansetron to avoid hospitalization 
and intravenous therapy for children diagnosed with 
gastroenteritis associated vomiting [21]. Back in 2009, 
antiemetics use among children of one to ten years of 
age was also reported in the emergencies [22]. Other 
surveys also reflect the use of ondansetron to treat 
acute gastritis in OPDs and emergencies [23 – 25]. 
With the availability of generic formula, the use of 
ondansetron will further increase. 
 
BASICS OF GOOD TREATMENT OF ACUTE 
GASTROENTERITIS: 
At present, the importance of oral rehydration therapy 
as key management of acute gastroenteritis cannot be 
negated as it is still the first choice of most of the 
physicians. Literature review shows that ondansetron 
reduces vomiting and increases the chances of success. 
It also reduces the onset of intravenous therapy and 
oral rehydration therapy compliance along with 
reduces stay at the hospital. 
 
No formal research has been carried out to study the 
medication and hospitalization cost. Ondansetron 
likely reduces both hospitalization and medication 
cost for acute gastroenteritis patients. No sedative 
effects are there and the safety profile is also good. 
Increased episodes of diarrhoea are the only drawback. 
Oral rehydration therapy refers to the management of 
disease at home which offers comfort for patient and 
parents. For vomiting, an only a single dose of 
ondansetron is sufficient. The oral dose is preferred 
than the intravenous route due to comfort and ease 
[26]. Antiemetics may pose potent value for severe 
vomiting episodes; however, it is not clearly stated in 
the given guidelines in order to select various types of 
antiemetics. Essential pillars of a suitable treatment 
program for the management of acute gastroenteritis 
include oral rehydration, hypotonic ORS, rapid oral 
rehydration (3 – 4 hours), rapid normal feeding, not to 
use special or diluted formula, all-time breastfeeding 
continuation and ORS supplementation. Moreover, 
selected patients may receive antiemetic medications 
as an essential medical intervention. 
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